Key result
Treatment with bevacizumab and combination chemotherapy resulted in partial remission, reduced chest pain, and 15 months of survival in a patient with stage IV scalp angiosarcoma.
Case Report (n=1)
Bevacizumab combined with chemotherapy is a potential treatment for scalp angiosarcoma, but its benefits must be weighed against the risk of venous thromboembolism.
Answers are grounded in this paper and cite their sources.
May support bevacizumab-chemotherapy for palliation in advanced scalp angiosarcoma; hypothesis-generating and requires prospective validation.
Bevacizumab, an angiogenesis inhibitor, is a recombined humanized monoclonal antibody against vascular endothelial growth factor and a promising therapeutic option for angiosarcoma management. This is a case report and review of the literature using bevacizumab and combination chemotherapy for angiosarcoma. The understanding of the effectiveness of combined therapy of bevacizumab and chemotherapy agents is still limited. The benefits of bevacizumab treatment for angiosarcoma will need to be weighed against the risks of venous thromboembolism in this population.
No takes yet. Share an insight, caveat, or question.
Yang et al. (2013) conducted a case report in Scalp angiosarcoma (n=1). Bevacizumab and combination chemotherapy was evaluated on Clinical response and survival. Treatment with bevacizumab and combination chemotherapy resulted in partial remission, reduced chest pain, and 15 months of survival in a patient with stage IV scalp angiosarcoma.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: